Literature DB >> 18324972

Increased CD177 (PRV1) expression in thalassaemia and the underlying erythropoietic activity.

Katerina Zoi1, Evangelos Terpos, Christine Zoi, Dimitris Loukopoulos.   

Abstract

CD177 (PRV1) expression is strongly related to polycythaemia vera (PV). Whilst studying CD177 expression in PV patients and controls, individuals with beta-thalassaemia minor were found to display an elevated expression of CD177. The study was expanded to include patients with thalassaemia intermedia, sickle cell/beta-thalassaemia and thalassaemia major. CD177 expression was increased in these thalassaemic groups and correlated with their erythropoietic activity, as assessed by the measurement of serum erythropoietin and soluble transferrin receptor levels. Within this context, elevated CD177 expression is not only a specific feature of PV but may be an indicator of increased erythropoietic activity in thalassaemia syndromes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18324972     DOI: 10.1111/j.1365-2141.2008.06993.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  3 in total

1.  Expression of adhesion factor CD239 in bone marrow cells in chronic myeloproliferative diseases.

Authors:  Kais Hussein; Katharina Theophile; Katrin Denzer; Hans Kreipe; Oliver Bock
Journal:  J Thromb Thrombolysis       Date:  2008-10-30       Impact factor: 2.300

2.  Study of serum haptoglobin level and its relation to erythropoietic activity in Beta thalassemia children.

Authors:  Seham M Ragab; Manal A Safan; Eman A Badr
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-02-15       Impact factor: 2.576

3.  Baseline and Disease-Induced Transcriptional Profiles in Children with Sickle Cell Disease.

Authors:  Susan Creary; Chandra L Shrestha; Kavitha Kotha; Abena Minta; James Fitch; Lisa Jaramillo; Shuzhong Zhang; Swaroop Pinto; Rohan Thompson; Octavio Ramilo; Peter White; Asuncion Mejias; Benjamin T Kopp
Journal:  Sci Rep       Date:  2020-06-02       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.